Ingliptin: Side Effects & Dosing

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing

Concise Prescribing Info

Contents

Sitagliptin phosphate

Indications/Uses

Adjunct to diet & exercise to improve glycemic control in adults w/ type 2 DM (non-insulin dependent) as monotherapy or combination therapy.

Click to view Ingliptin detailed prescribing information

Dosage/Direction for Use

Adult 1 tab once daily. Concomitant therapy w/ insulin or insulin secretagogue (eg, sulfonylurea), thiazolidinediones (eg, pioglitazone, rosiglitazone) w/ or w/o metformin 100 mg once daily. Moderate renal impairment (CrCl 30 to <50 mL/min) 50 mg once daily, severe renal impairment (CrCl <30 mL/min) or ESRD requiring hemodialysis or peritoneal dialysis 25 mg once daily.

Click to view Ingliptin detailed prescribing information

Overdosage

View Ingliptin overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food.

Contraindications

Patients w/ known serious hypersensitivity (eg, anaphylaxis, angioedema).

Click to view Ingliptin detailed prescribing information

Special Precautions

Serious hypersensitivity & allergic reactions eg, angioedema, anaphylaxis & SJS, particularly w/in 1st 3 mth of treatment. Discontinue therapy if signs & symptoms of acute pancreatitis, including fatal & non-fatal hemorrhagic & necrotizing pancreatitis develop; blisters or erosions develop or bullous pemphigoid is suspected. Consider discontinuation if heart failure occurs. Not for patients w/ type 1 DM; diabetic ketoacidosis. Severe & disabling arthralgia. Moderate or severe renal insufficiency; ESRD requiring hemodialysis or peritoneal dialysis. Not recommended during pregnancy. Not to be used by nursing women.

Click to view Ingliptin detailed prescribing information

Use In Pregnancy & Lactation

Click to view Ingliptin detailed prescribing information

Adverse Reactions

Hypoglycemia; diarrhea, nausea; increased serum creatinine; nasopharyngitis. Acute pancreatitis (including hemorrhagic or necrotizing forms), acute renal failure (possibly requiring dialysis), anaphylaxis, angioedema, arthralgia, back pain, bullous pemphigoid, constipation, exfoliative dermatitis, headache, hypersensitivity, hypersensitivity vasculitis, increased liver enzymes, limb pain, myalgia, oral mucosa ulcer, pain, pemphigoid, pruritus, renal insufficiency, severe arthralgia, skin rash (including macular), SJS, stomatitis, urticaria, vomiting.

Click to view Ingliptin detailed prescribing information

Drug Interactions

May increase levels/effects of ACE inhibitors, digoxin, hypoglycemia-associated agents, insulins, sulfonylureas. May increase levels/effects w/ α-lipoic acid, androgens, guanethidine, lumacaftor, MAOIs, pegvisomant, P-gp/ABCB1 inhibitors, prothionamide, quinolones, ranolazine, salicylates, SSRIs. May decrease levels/effects w/ hyperglycemia-associated agents, lumacaftor, P-gp/ABCB1 inducers, quinolones, thiazide & thiazide-like diuretics.

Click to view Ingliptin detailed prescribing information

Storage

View Ingliptin storage conditions for details to ensure optimal shelf-life.

Description

View Ingliptin description for details of the chemical structure and excipients (inactive components).

Action

View Ingliptin mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antidiabetic Agents

ATC Classification

A10BH01 - sitagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.

Thai FDA Category

Presentation/Packing

Form

Ingliptin FC tab 100 mg

Packing/Price

3 × 10's

Ingliptin

sitagliptin

Manufacturer:

Community Pharm PCL

Distributor:

Community Pharm PCL

Marketer:

Community Pharm PCL